Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Capital Leases (2021 - 2024)

Lexaria Bioscience's Capital Leases history spans 4 years, with the latest figure at $109319.0 for Q3 2024.

  • For Q3 2024, Capital Leases fell 19.72% year-over-year to $109319.0; the TTM value through Aug 2024 reached $109319.0, down 19.72%, while the annual FY2024 figure was $109319.0, 19.72% down from the prior year.
  • Capital Leases for Q3 2024 was $109319.0 at Lexaria Bioscience, down from $115327.0 in the prior quarter.
  • Across five years, Capital Leases topped out at $142587.0 in Q2 2023 and bottomed at $7401.0 in Q3 2022.
  • The 4-year median for Capital Leases is $118906.5 (2024), against an average of $101599.9.
  • The largest annual shift saw Capital Leases crashed 85.19% in 2022 before it skyrocketed 1739.93% in 2023.
  • A 4-year view of Capital Leases shows it stood at $49989.0 in 2021, then plummeted by 85.19% to $7401.0 in 2022, then surged by 1649.99% to $129517.0 in 2023, then decreased by 15.59% to $109319.0 in 2024.
  • Per Business Quant, the three most recent readings for LEXX's Capital Leases are $109319.0 (Q3 2024), $115327.0 (Q2 2024), and $122486.0 (Q1 2024).